Important 3 New Studies on Mercury and Autism
This update is from Dr. Mark Geier & David Geier
This is a status update regarding the continuing avalanche of ever increasing numbers of studies that are emphatically supporting and extending the theory that mercury exposure, and particularly, mercury exposure from Thimerosal-containing vaccines plays a significant role in causing autism and other neurodevelopmental disorders.
First, and perhaps most importantly, is the first epidemiological peer-reviewed study on US children (other than our own extensive body of peer-reviewed studies) to show a statistically significant increased risk for neurodevelopmental disorders following exposure to increasing doses of mercury from Thimerosal-containing childhood vaccines. This study is saved as Hepatitis B triple series vaccine and developmental disability in US children aged 1-9 years1 in Adobe Acrobat Format. www.sarnet.org/lib/hepBdds.pdf
This study was published in the journal of Toxicological and Environmental Chemistry by newly published researchers on Thimerosal from the School of Public Health, Stony Brook University Medical Center, Health Sciences Center, State University of New York at Stony Brook.
These researchers reported their, "study investigated the association between the hepatitis B triple series vaccination in children age 1-9 years and developmental disability, proxied by parental report of early intervention or special education services (EIS) in the 1999-2000 National Health and Nutrition Examination Survey (NHANES)."
Further, they stated, "while this study uses EIS as a proxy for developmental disability in general, but not specifically autism, autism merits consideration because it is a developmental disorder with recent notable impacts on EIS. The number of children receiving special education services for autism increased 500% from 1991/92 to 1998/99 (CDC 2007b)."
Finally, "vaccination with hepatitis B triple series vaccine during the time period vaccines were manufactured with Thimerosal exposed newborns and infants to ethylHg (CDC 2000). By using NHANES 1999-2000 data for children age 1-9 years of age, children who were candidates for the Thimerosal-containing triple series hepatitis B vaccine were included in the study sample. The eldest children who received the triple series